Clinical Trial

The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this exploratory study was to investigate the instant efficacy and safety of alverine oral administration in decreasing portal hypertension. Condition of disease: Cirrhotic portal hypertension Intervention/treatment: Drug: Alverine 60 mg (1 capsule), orally Drug: Alverine 120 mg (2 capsules), orally
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-18.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-02-23
Trial Details
NCT Number NCT05508633
Lead Sponsor Shanghai Changzheng Hospital
Conditions Portal Hypertension
Enrollment 20 participants
Start Date 2022-10-28
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-25